During continuous renal replacement therapy, achievement of recommended treatment dose is important. However, relevant substrate loss may occur and recommended nutrition during critical illness could not be sufficient for higher dialysis doses. We investigated the correlation of dialysis dose and substrate loss for a broad range of dialysis doses.
Forty critically ill patients with acute kidney injury undergoing citrate CVVHD were included in this prospective study. Three different corresponding blood flow (BF) and dialysate flow (DF) rates were applied (BF/DF: 100 ml/min, 2000 ml/h; 80 ml/min, 1500 ml/h; 120 ml/min, 2500 ml/h). Delivered effluent flow rate (DEFR) was calculated and correlated with losses of vitamins, electrolytes, and trace elements during recommended nutritional supplementation.
For folic acid, vitamin B12, zinc, inorganic phosphate, and magnesium, no correlation of losses and DEFR was detected. For ionized calcium, a correlation was observed and additional substitution was required.
Clinically relevant loss of folic acid, vitamin B12, zinc, inorganic phosphate, and magnesium was not observed for differently used dialysis doses of CVVHD, and the loss was covered sufficiently by daily recommended nutritional supplementation. Increased loss of ionized calcium for higher dialysis doses occurred during citrate CVVHD. Therefore, a strict protocol must maintain calcium homeostasis to avoid calcium depletion.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Fayad AI, Buamscha DG, Ciapponi A (2016) Intensity of continuous renal replacement therapy for acute kidney injury. Cochrane Database Syst Rev 10:cd010613. https://doi.org/10.1002/14651858.cd010613.pub2
Mehta RL, McDonald BR, Aguilar MM, Ward DM (1990) Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int 38(5):976–981
Morgera S, Schneider M, Slowinski T, Vargas-Hein O, Zuckermann-Becker H, Peters H, Kindgen-Milles D, Neumayer H-H (2009) A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status. Crit Care Med 37(6):2018–2024. https://doi.org/10.1097/CCM.0b013e3181a00a92
Palsson R, Niles JL (1999) Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Kidney Int 55(5):1991–1997. https://doi.org/10.1046/j.1523-1755.1999.00444.x
Overberger P, Pesacreta M, Palevsky PM (2007) Management of renal replacement therapy in acute kidney injury: a survey of practitioner prescribing practices. Clin J Am Soc Nephrol 2(4):623–630. https://doi.org/10.2215/cjn.00780207
Churchwell MD, Pasko DA, Btaiche IF, Jain JC, Mueller BA (2007) Trace element removal during in vitro and in vivo continuous haemodialysis. Nephrol Dial Transplant 22(10):2970–2977. https://doi.org/10.1093/ndt/gfm352
Pasko DA, Churchwell MD, Btaiche IF, Jain JC, Mueller BA (2009) Continuous venovenous hemodiafiltration trace element clearance in pediatric patients: a case series. Pediatr Nephrol (Berlin Germany) 24(4):807–813. https://doi.org/10.1007/s00467-008-1083-8
Datzmann T, Träger K, Reinelt H, von Freyberg P (2017) Elimination rates of electrolytes, vitamins, and trace elements during continuous renal replacement therapy (CRRT) with citrate CVVHD—influence of filter lifetime. Blood Purif 44(3):210–216. https://doi.org/10.1159/000477454
Berger MM, Shenkin A, Revelly J-P, Roberts E, Cayeux MC, Baines M, Chiolero RL (2004) Copper, selenium, zinc, and thiamine balances during continuous venovenous hemodiafiltration in critically ill patients. Am J Clin Nutr 80(2):410–416
Section 2: AKI Definition (2012) Kidney Int Suppl 2(1):19–36. https://doi.org/10.1038/kisup.2011.32
Biesalski HK, Bischoff SC, Boehles HJ, Muehlhoefer A (2009) Water, electrolytes, vitamins and trace elements: guidelines on parenteral nutrition, Chapter 7. German Med Sci 7:Doc21. https://doi.org/10.3205/000080
Lee JW (2010) Fluid and electrolyte disturbances in critically ill patients. Electrolyte Blood Press 8(2):72–81. https://doi.org/10.5049/ebp.2010.8.2.72
Lamers Y (2011) Indicators and methods for folate, vitamin B-12, and vitamin B-6 status assessment in humans. Curr Opin Clin Nutr Metab Care 14(5):445–454. https://doi.org/10.1097/MCO.0b013e328349f9a7
Berger MM, Shenkin A (2007) Trace element requirements in critically ill burned patients. J Trace Elem Med Biol 21(Suppl 1):44–48. https://doi.org/10.1016/j.jtemb.2007.09.013
Klein CJ, Moser-Veillon PB, Schweitzer A, Douglass LW, Reynolds HN, Patterson KY, Veillon C (2002) Magnesium, calcium, zinc, and nitrogen loss in trauma patients during continuous renal replacement therapy. JPEN J Parenter Enteral Nutr 26(2):77–92 discussion 92–73
Tolwani A, Wille KM (2012) Advances in continuous renal replacement therapy: citrate anticoagulation update. Blood Purif 34(2):88–93. https://doi.org/10.1159/000342378
Davenport A, Tolwani A (2009) Citrate anticoagulation for continuous renal replacement therapy (CRRT) in patients with acute kidney injury admitted to the intensive care unit. NDT Plus 2(6):439–447. https://doi.org/10.1093/ndtplus/sfp136
Oudemans-van Straaten HM, Ostermann M (2012) Bench-to-bedside review: citrate for continuous renal replacement therapy, from science to practice. Crit Care 16(6):249. https://doi.org/10.1186/cc11645
Wang PL, Meyer MM, Orloff SL, Anderson S (2004) Bone resorption and “relative” immobilization hypercalcemia with prolonged continuous renal replacement therapy and citrate anticoagulation. Am J Kidney Dis 44(6):1110–1114
Section 5: Dialysis Interventions for Treatment of AKI (2012). Kidney Int Suppl (2011) 2(1):89–115. https://doi.org/10.1038/kisup.2011.35
Prowle JR, Schneider A, Bellomo R (2011) Clinical review: optimal dose of continuous renal replacement therapy in acute kidney injury. Crit Care 15(2):207. https://doi.org/10.1186/cc9415
Venkataraman R, Kellum JA, Palevsky P (2002) Dosing patterns for continuous renal replacement therapy at a large academic medical center in the United States. J Crit Care 17(4):246–250. https://doi.org/10.1053/jcrc.2002.36757
The authors would like to acknowledge the support of Gerald Steinbach from the Department of Clinical Chemistry at the University Hospital Ulm.
Conflict of interest
Karl Träger received honoraria for lectures from Fresenius Medical Care.
About this article
Cite this article
Datzmann, T., Träger, K., Schröppel, B. et al. Treatment dose and the elimination rates of electrolytes, vitamins, and trace elements during continuous veno-venous hemodialysis (CVVHD). Int Urol Nephrol 50, 1143–1149 (2018). https://doi.org/10.1007/s11255-018-1856-3
- Acute kidney injury
- Continuous renal replacement therapy
- Citrate anticoagulation
- Critical illness
- Trace elements